These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 22153896)

  • 1. Canine intestinal mast cell tumor with c-kit exon 8 mutation responsive to imatinib therapy.
    Kobayashi M; Sugisaki O; Ishii N; Yamada O; Ito K; Kuroki S; Sasaki Y; Ono K; Washizu T; Bonkobara M
    Vet J; 2012 Jul; 193(1):264-7. PubMed ID: 22153896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.
    Isotani M; Tamura K; Yagihara H; Hikosaka M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2006 Nov; 114(1-2):168-72. PubMed ID: 16908071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not all c-kit mutations can be corrected by imatinib.
    Lasota J
    Lab Invest; 2007 Apr; 87(4):317. PubMed ID: 17486696
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutations in the fifth immunoglobulin-like domain of kit are common and potentially sensitive to imatinib mesylate in feline mast cell tumours.
    Isotani M; Yamada O; Lachowicz JL; Tamura K; Yagihara H; Fujino Y; Ono K; Washizu T; Bonkobara M
    Br J Haematol; 2010 Jan; 148(1):144-53. PubMed ID: 19804453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib-associated tumour response in a dog with a non-resectable gastrointestinal stromal tumour harbouring a c-kit exon 11 deletion mutation.
    Kobayashi M; Kuroki S; Ito K; Yasuda A; Sawada H; Ono K; Washizu T; Bonkobara M
    Vet J; 2013 Oct; 198(1):271-4. PubMed ID: 23820134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.
    Mital A; Piskorz A; Lewandowski K; Wasąg B; Limon J; Hellmann A
    Eur J Haematol; 2011 Jun; 86(6):531-5. PubMed ID: 21362052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
    Nakagomi N; Hirota S
    Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
    Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
    Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tyrosine kinase inhibition by imatinib mesylate on mast cell tumors in dogs.
    Isotani M; Ishida N; Tominaga M; Tamura K; Yagihara H; Ochi S; Kato R; Kobayashi T; Fujita M; Fujino Y; Setoguchi A; Ono K; Washizu T; Bonkobara M
    J Vet Intern Med; 2008; 22(4):985-8. PubMed ID: 18564222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.
    Akin C; Fumo G; Yavuz AS; Lipsky PE; Neckers L; Metcalfe DD
    Blood; 2004 Apr; 103(8):3222-5. PubMed ID: 15070706
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib for systemic mast-cell disease.
    Pardanani A; Elliott M; Reeder T; Li CY; Baxter EJ; Cross NC; Tefferi A
    Lancet; 2003 Aug; 362(9383):535-6. PubMed ID: 12932387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a secondary mutation in the KIT kinase domain correlated with imatinib-resistance in a canine mast cell tumor.
    Nakano Y; Kobayashi M; Bonkobara M; Takanosu M
    Vet Immunol Immunopathol; 2017 Jun; 188():84-88. PubMed ID: 28615132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ex vivo evaluation of imatinib mesylate for induction of cell death on canine neoplastic mast cells with mutations in c-Kit exon 11 via apoptosis.
    Rossi G; Bertani C; Mari S; Marini C; Renzoni G; Ogilvie G; Magi GE
    Vet Res Commun; 2013 Jun; 37(2):101-8. PubMed ID: 23315207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).
    Peter B; Hadzijusufovic E; Blatt K; Gleixner KV; Pickl WF; Thaiwong T; Yuzbasiyan-Gurkan V; Willmann M; Valent P
    Exp Hematol; 2010 Sep; 38(9):782-91. PubMed ID: 20685234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic mastocytosis: current classification and novel therapeutic options.
    Barbie DA; Deangelo DJ
    Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
    Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.